XML 48 R14.htm IDEA: XBRL DOCUMENT
v3.10.0.1

Financial Instruments | 6 Months Ended
--- | ---
Jun. 30, 2018
Investments, Debt and Equity Securities [Abstract] |
Financial Instruments | Financial Instruments The following table summarizes our financial assets with maturities of less than 90 days from the date of purchase included in cash and cash equivalents in our condensed consolidated balance sheets:
(In millions) | As of June 30, 2018 |  | As of December 31, 2017
Commercial paper | $ | 125.2 |  |  | $ | 30.5 |
Overnight reverse repurchase agreements | 23.9 |  |  | 3.6 |
Money market funds | 541.7 |  |  | 948.0 |
Short-term debt securities | 41.4 |  |  | 247.3 |
Total | $ | 732.2 |  |  | $ | 1,229.4 |
The carrying values of our commercial paper, including accrued interest, overnight reverse repurchase agreements, money market funds and short-term debt securities approximate fair value due to their short-term maturities. Upon the adoption of ASU 2016-01, our marketable equity securities gains (losses) are recorded in other income (expense), net in our condensed consolidated statements of income. The following tables summarize our marketable debt and equity securities, classified as available-for-sale:
As of June 30, 2018 (In millions) | Fair Value |  | Gross Unrealized Gains |  | Gross Unrealized Losses |  | Amortized Cost
Corporate debt securities |  |  |  |  |  |  |
Current | $ | 1,484.2 |  |  | $ | 0.1 |  |  | $ | (0.7 | ) |  | $ | 1,484.8 |
Non-current | 561.3 |  |  | 0.4 |  |  | (0.6 | ) |  | 561.5 |
Government securities |  |  |  |  |  |  |
Current | 489.6 |  |  | — |  |  | (0.1 | ) |  | 489.7 |
Non-current | 339.1 |  |  | 0.1 |  |  | (0.6 | ) |  | 339.6 |
Mortgage and other asset backed securities |  |  |  |  |  |  |
Current | 0.2 |  |  | — |  |  | — |  |  | 0.2 |
Non-current | 259.8 |  |  | 0.1 |  |  | (0.8 | ) |  | 260.5 |
Total marketable debt securities | $ | 3,134.2 |  |  | $ | 0.7 |  |  | $ | (2.8 | ) |  | $ | 3,136.3 |
Marketable equity securities, non-current | $ | 489.7 |  |  | $ | 42.5 |  |  | $ | (49.4 | ) |  | $ | 496.6 |
As of December 31, 2017 (In millions) | Fair Value |  | Gross Unrealized Gains |  | Gross Unrealized Losses |  | Amortized Cost
Corporate debt securities |  |  |  |  |  |  |
Current | $ | 1,039.3 |  |  | $ | — |  |  | $ | (0.2 | ) |  | $ | 1,039.5 |
Non-current | 1,570.5 |  |  | 0.9 |  |  | — |  |  | 1,569.6 |
Government securities |  |  |  |  |  |  |
Current | 1,075.1 |  |  | 0.1 |  |  | (0.7 | ) |  | 1,075.7 |
Non-current | 844.2 |  |  | 0.2 |  |  | (1.1 | ) |  | 845.1 |
Mortgage and other asset backed securities |  |  |  |  |  |  |
Current | 0.8 |  |  | — |  |  | — |  |  | 0.8 |
Non-current | 642.6 |  |  | 1.1 |  |  | (0.8 | ) |  | 642.3 |
Total marketable debt securities | $ | 5,172.5 |  |  | $ | 2.3 |  |  | $ | (2.8 | ) |  | $ | 5,173.0 |
Marketable equity securities, non-current | $ | 11.8 |  |  | $ | 1.8 |  |  | $ | (4.4 | ) |  | $ | 14.4 |
Summary of Contractual Maturities: Available-for-Sale Securities The estimated fair value and amortized cost of our marketable debt securities available-for-sale by contractual maturity are summarized as follows:
| As of June 30, 2018 |  | As of December 31, 2017
(In millions) | Estimated Fair Value |  | Amortized Cost |  | Estimated Fair Value |  | Amortized Cost
Due in one year or less | $ | 1,974.0 |  |  | $ | 1,974.7 |  |  | $ | 2,115.2 |  |  | $ | 2,116.0 |
Due after one year through five years | 1,063.5 |  |  | 1,064.5 |  |  | 2,730.0 |  |  | 2,730.0 |
Due after five years | 96.7 |  |  | 97.1 |  |  | 327.3 |  |  | 327.0 |
Total available-for-sale securities | $ | 3,134.2 |  |  | $ | 3,136.3 |  |  | $ | 5,172.5 |  |  | $ | 5,173.0 |
The average maturity of our marketable debt securities available-for-sale as of June 30, 2018 and December 31, 2017, was approximately 10 months and 17 months, respectively. Proceeds from Marketable Debt Securities The proceeds from maturities and sales of marketable debt securities and resulting realized gains and losses are summarized as follows:
| For the Three Months Ended June 30, |  | For the Six Months Ended June 30,
(In millions) | 2018 |  | 2017 |  | 2018 |  | 2017
Proceeds from maturities and sales | $ | 2,733.7 |  |  | $ | 1,700.2 |  |  | $ | 6,802.7 |  |  | $ | 3,584.5 |
Realized gains | $ | 0.8 |  |  | $ | 1.2 |  |  | $ | 2.6 |  |  | $ | 2.4 |
Realized losses | $ | (0.8 | ) |  | $ | (1.3 | ) |  | $ | (10.2 | ) |  | $ | (3.2 | )
Strategic Investments As of June 30, 2018 and December 31, 2017, our strategic investment portfolio was comprised of investments totaling $549.0 million and $85.8 million, respectively, which are included in investments and other assets in our condensed consolidated balance sheets. The increase in our strategic investment portfolio is a result of our investment in Ionis' common stock, as discussed below. Our strategic investment portfolio includes investments in equity securities of certain biotechnology companies and investments in venture capital funds where the underlying investments are in equity securities of certain biotechnology companies. Our investments in equity securities of certain publicly-traded biotechnology companies are regularly measured and carried at fair value and classified as Level 1 marketable equity securities within our disclosures included in Note 7, Fair Value Measurements, to these condensed consolidated financial statements. Our investment in Ionis' common stock will be regularly measured and carried at fair value and classified as a Level 2 marketable equity security within our disclosures in Note 7, Fair Value Measurements, to these condensed consolidated financial statements. Ionis Pharmaceuticals, Inc. In June 2018 we completed a new ten-year exclusive collaboration with Ionis to develop novel antisense oligonucleotide drug candidates for a broad range of neurological diseases for a total payment of $1.0 billion consisting of an upfront payment of $375.0 million and the purchase of approximately 11.5 million shares of Ionis' common stock at a cost of $625.0 million. Our investment in Ionis' common stock is remeasured each reporting period and carried at fair value. The effects of the holding period restrictions are estimated using an option pricing valuation model. The most significant assumptions within the model are the term of the restrictions and the stock price volatility, which is based upon historical volatility of similar companies. We also use a constant maturity risk free-interest rate to match the remaining term of the restrictions on our investment in Ionis' common stock and a dividend yield of zero based upon the fact that Ionis and similar companies generally have not historically granted cash dividends. For additional information on our new collaboration agreement with Ionis, please read Note 18, Collaborative and Other Relationships, to these condensed consolidated financial statements.

X
- Definition The entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss). + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 305 -URI http://asc.fasb.org/topic&trid=2122426 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 320 -URI http://asc.fasb.org/topic&trid=2196928 + Details
Name: | us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration